Dicot has started manufacturing of the study drug for clinical trials in line with the schedule

Press release: Uppsala, February 20, 2023. Dicot announces that the GMP manufacturing of the study drug for the planned phase 1 studies has begun. This is completely in line with the company's time schedule for start of clinical studies. The manufacture refers to both study drugs with active substance and placebo.

Dicot has previously announced that Thermo Fischer Scientific has been contracted for GMP (Good Manufacturing Practice) manufacturing of the study drug for the company's phase 1 studies. Today, Dicot announces that production has started. This is completely in line with the overall time plan for the start of clinical studies during middle of the year. Both study drugs with active substance and placebo will be manufactured, which is required for the implementation of the phase 1 clinical studies.

"I'm very happy that the manufacture of the study drug is now ongoing and that we are in line with the overall time plan. Manufacturing is a very important preparatory step for the start of a clinical trial," comments Elin Trampe, CEO at Dicot.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 739 80 14 08
E-mail: [email protected]

About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.

Om Dicot Pharma

Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.



Kurs ()
Förändring ()
Marknad Spotlight Stock Market Kortnamn DICOT ISIN-kod SE0011178458


Elin Trampe Vd